Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer

Kumar, Rakesh; Chauhan, Anil; Zhuang, Hongming; Chandra, Prem; Schnall, Mitchell D.; Alavi, Abass

doi:10.1007/s10549-006-9159-2

Cited by 189 publications

(127 citation statements)

References 20 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Thus, 79 lesions were evaluated in 78 patients. In our institute, the 18 F-FDG PET/CT scan is performed for tumors larger than 1.0 cm in diameter because of the frequency of false-negative PET results in tumors of diameter less than 1.0 cm [6]. Breast carcinoma was diagnosed by recent trocar needle biopsy in all patients before 18 F-FDG PET/CT imaging.…”

Section: Methods Patientsmentioning

confidence: 99%

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

et al. 2016

View full text Add to dashboard Cite

The aims of this retrospective study were to consider the diagnostic role of dual-time 18 F-fluorodeoxyglucose positron emission tomography and computed tomography ( 18 F-FDG PET/CT) in detection of breast carcinoma and axillary lymph node (ALN) status and to evaluate the primary tumor 18 F-FDG uptake pattern. Preoperative staging was performed by 18 F-FDG PET/CT in 78 female patients with breast carcinoma. Conventional imaging results were evaluated by breast magnetic resonance imaging (MRI) of 79 lesions in 78 patients, bilateral mammography (MMG) of 40 lesions in 40 patients, and breast ultrasonography (USG) of 47 lesions in 46 patients. The primary tumor detection rate using 18 F-FDG PET/CT was higher than those using MRI, USG, and MMG. The sensitivity and specificity of 18 F-FDG PET/CT scans for detecting multifocality were higher than those of MRI. The specificity of ALN metastasis detection with MRI was higher than that with 18 F-FDG PET/CT, but 18 F-FDG PET/CT had higher sensitivity. Higher 18 F-FDG uptake levels were detected in patients with ALN metastasis, histologic grade 3, estrogen-progesterone-negative receptor status, lymphatic invasion, and moderate to poor prognostic groups. There was no statistical difference for the retention index in categorical pathological parameters except for progesterone-negative status.In conclusion, 18 F-FDG PET/CT scans may be a valuable imaging technique for evaluating primary tumor and axillary status in staging breast carcinoma and 18 F-FDG uptake may be a prognostic factor that indicates aggressive tumor biology and poor prognosis. Dual-time imaging in breast carcinoma staging may not be used for predicting pathological criteria and the aggressiveness of primary lesions.

show abstract

Section: Methods Patientsmentioning

confidence: 99%

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…We also observed that the SUV max was related directly to primary tumor size in patients with breast cancer. 25 We have demonstrated that the SUV max increases as tumor size increases, and vice versa. Kidd et al demonstrated that the SUV max is a stronger predictor of overall survival than tumor volume or lymph node status.…”

mentioning

confidence: 71%

¹⁸F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix

Kumar

Dadparvar

2007

Cancer

Self Cite

View full text Add to dashboard Cite

Lentivirus‐derived vectors (LVs) were studied for the generation of stable recombinant Chinese hamster ovary (CHO) cell lines. Stable pools and clones expressing the enhanced green fluorescent protein (eGFP) were selected via fluorescence‐activated cell sorting (FACS). For comparison, cell pools and cell lines were also generated by transfection, using the LV transfer plasmid alone. The level and stability of eGFP expression was greater in LV‐transduced cell lines and pools than in those established by transfection. CHO cells were also infected at two different multiplicities of infection with an LV co‐expressing eGFP and a tumor necrosis factor receptor:Fc fusion protein (TNFR:Fc). At 2‐day post‐infection, clonal cell lines with high eGFP‐specific fluorescence were recovered by FACS. These clones co‐expressed TNFR:Fc with yields of 50–250 mg/L in 4‐day cultures. The recovered cell lines maintained stable expression over 3 months in serum‐free suspension culture without selection. In conclusion, LV‐mediated gene transfer provided an efficient alternative to plasmid transfection for the generation of stable and high‐producing recombinant cell lines. Biotechnol. Bioeng. 2011; 108:600–610. © 2010 Wiley Periodicals, Inc.

show abstract

“…This is due to the limited spatial resolution of PET and, in some cases, by tumor characteristics (e.g., low FDG avidity in grade 1 cancer, ductal carcinoma in situ, or lobular carcinoma) [1,2]. Specificity can also be altered by variations of FDG uptake in certain benign conditions, such as infection, fibroadenoma, ductal adenoma, inflammatory granulomatous mastitis, and fibrocystic changes [3].…”

Section: Diagnosismentioning

confidence: 99%

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Kitajima

Miyoshi

2016

Jpn J Radiol

View full text Add to dashboard Cite

by malignant cells, opened a new field in clinical oncologic imaging. Recently, integrated positron emission tomography/computed tomography (PET/CT), in which a full-ringdetector clinical PET scanner and multidetector-row helical CT scanner are combined, has made it possible to acquire both metabolic and anatomic imaging data using a single device in a single diagnostic session, and provides precise anatomic localization of suspicious areas of increased FDG uptake. When used in a clinical setting, FDG-PET/CT leads to a significant improvement in diagnostic accuracy and has had a considerable impact on patient management, including diagnosis, initial staging, optimization of treatment, restaging, monitoring of the response to therapy, and prognostication of various malignant tumors. We herein review the current and future roles of FDG-PET/CT in the management of breast cancer, discussing its usefulness and limitations for imaging in these patients. DiagnosisFDG-PET imaging has poor sensitivity (<50 %) for subcentimeter breast cancers [9,10]. This is due to the limited spatial resolution of PET and, in some cases, by tumor characteristics (e.g., low FDG avidity in grade 1 cancer, ductal carcinoma in situ, or lobular carcinoma) [1,2]. Specificity can also be altered by variations of FDG uptake in certain benign conditions, such as infection, fibroadenoma, ductal adenoma, inflammatory granulomatous mastitis, and fibrocystic changes [3].In order to improve specificity, some authors would obtain a second series of PET images centered on the breast approximately 2 h after FDG injection (dual-time imaging) [4]. Indeed, FDG uptake seems to increase with time in the case of malignancy, while some inflammatory lesions show stable or decreasing uptake [4]. However, dual-time Abstract Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxyd-glucose (FDG) is a useful tool for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the diagnosis, initial staging, restaging, early treatment response assessment, evaluation of metastatic disease response, and prognostication of breast cancer as well as various malignant tumors. We herein review the current place and role of FDG-PET/CT in the management of breast cancer, focusing on its usefulness and limitations in the imaging of these patients.

show abstract

Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer

Abstract: In present study, tumor size and tumor grade are independent factors that predict FDG-PET results. Smaller tumors (< or =10 mm) and low-grade tumors are strong predictor of FN FDG-PET results.

Cited by 189 publications

References 20 publications

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

¹⁸F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Contact Info

Product

Resources

About

Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer

Abstract: In present study, tumor size and tumor grade are independent factors that predict FDG-PET results. Smaller tumors (< or =10 mm) and low-grade tumors are strong predictor of FN FDG-PET results.

Cited by 189 publications

References 20 publications

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors

18F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Contact Info

Product

Resources

About

¹⁸F‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (PET)/PET‐computed tomography in carcinoma of the cervix